At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Trading 10-07 09:59:08 EDT
413.81
+11.21
+2.78%
High413.85Low401.85Vol326.99K
Open403.06D1 Closing402.60Amplitude2.98%
Mkt Cap222.83BTradable Cap222.21BTotal Shares538.48M
T/O133.53MT/O Rate0.06%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Morgan Stanley Adjusts Price Target on Amgen to $359 From $362
MT Newswires Live  ·  20:56
Morgan Stanley Adjusts Price Target on Amgen to $359 From $362
Why Vaxcyte Chose A 1.5% Convertible
Macro World​  ·  14:39
Why Vaxcyte Chose A 1.5% Convertible
Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race
TIPRANKS  ·  00:31
Amgen’s AMG 513 Obesity Trial Reaches Phase 1 Completion, Adding a New Angle to the Weight-Loss Drug Race
From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run
Bellwether Stocks Movement  ·  10-06 10:42
From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run
One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet
Bellwether Stocks Movement  ·  10-05 15:29
One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet
Merck Doubled Off Its Lows — And Analysts Still See More Room
Bellwether Stocks Movement  ·  10-05 14:41
Merck Doubled Off Its Lows — And Analysts Still See More Room
CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2
Bellwether Stocks Movement  ·  10-05 10:38
CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2
Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs
Macro World​  ·  10-03
Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs
23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook
Bellwether Stocks Movement  ·  10-03
23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook
Amgen Inc. Stock Underperforms Friday When Compared to Competitors
Dow Jones  ·  10-03
Amgen Inc. Stock Underperforms Friday When Compared to Competitors
Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise
TIPRANKS  ·  10-03
Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise
Novartis Bets $7.8 Billion On MRNA Beyond Vaccines
Options & Short Sell  ·  10-02
Novartis Bets $7.8 Billion On MRNA Beyond Vaccines
Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors
Dow Jones  ·  10-02
Sino Biopharmaceutical Stock Falls 2.3% in Hong Kong, Underperforms Competitors
Quantum Computing is Having a Moment. What to Know About the Hottest Sector After AI.
Dow Jones  ·  10-02
Quantum Computing is Having a Moment. What to Know About the Hottest Sector After AI.
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know
TradingKey  ·  10-02
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know
Movement Alert｜Amgen Declines 3.12% in Regular Trading, Trading at $408.245
Market Focus  ·  10-02
Movement Alert｜Amgen Declines 3.12% in Regular Trading, Trading at $408.245
NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01
Reuters  ·  10-02
NASDAQ Top and Bottom Performing Stocks at About 02:45 P.m. EDT on 2026-10-01
Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth
TIPRANKS  ·  10-02
Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth
Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall
Dow Jones  ·  10-02
Walt Disney, Amgen Share Losses Lead Dow's 150-Point Fall
23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?
Options & Short Sell  ·  10-01
23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--